Full text is available at the source.
Abstract
The peptide-nanocomplex demonstrated stable particle formation under 200 nm and retained mRNA expression for up to 7 days in vivo.
- Lipid nanoparticles (LNPs) often accumulate in the liver and show transient protein expression, which can limit their effectiveness.
- The developed peptide-nanocomplex is composed of three functional peptides, including an RNA-binding peptide, charge-modulating polyglutamic acid, and an APC-targeting cell-penetrating peptide with a new immune cell-binding motif.
- The peptide-nanocomplex remained localized at the injection site and effectively drained to the lymph nodes, unlike LNPs.
- Mice immunized with SARS-CoV-2 spike mRNA using the peptide-nanocomplex showed robust neutralizing antibody titers comparable to those from LNPs.
- The peptide-nanocomplex induced significantly higher CD8+ T cell responses than LNPs.
- No toxicity was observed in vivo after daily injections for two weeks at doses up to 200 times higher than safe levels.
Simplified
mRNA Technology